DATA GRAPHICS | Regulation
Data Bytes: Drug approvals in Japan
June 30, 2020 2:45 AM UTC
On Monday, Japan’s Ministry of Health, Labour and Welfare announced at least nine drug approvals, five of which are products from Novartis AG (NYSE:NVS; SIX:NOVN).
Two of the approvals are for HIF-PH inhibitors to treat anemia due to chronic kidney disease. The Japanese approvals are the first ever for Duvroq daprodustat from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Vafseo vadadustat from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) and Akebia Therapeutics Inc. (NASDAQ:AKBA). ...